Aerovate Therapeutics, Inc.
AVTENASDAQHealthcare
$2.68
+$0.00(+0.00%)
Market Cap$77679800
P/E Ratio—
52W High$884.975
52W Low$2.6296
Aerovate Therapeutics, Inc. (AVTE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AVTE · earnings · updated Jun 10, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 10, 2025EPS Actual
-$0.64
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 10, 2025
After Market Close
AVTE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2025 | Nov 10, 2025 | — | -$0.64 | — | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.25 | -$1.13 | -352.1% | — | — | — |
| ▲ Q2 FY2025 | Apr 25, 2025 | -$0.30 | -$0.09 | +70.0% | — | — | — |
| — Q1 FY2025 | Mar 27, 2025 | -$0.19 | -$0.19 | +0.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.59 | -$0.56 | +5.1% | — | — | — |
| ▼ Q3 FY2024 | Aug 12, 2024 | -$0.76 | -$0.86 | -13.2% | — | — | — |
| ▼ Q2 FY2024 | May 13, 2024 | -$0.74 | -$0.83 | -12.2% | — | — | — |
| ▼ Q1 FY2024 | Mar 25, 2024 | -$0.68 | -$0.74 | -8.8% | $0.00B | — | — |
Q4 FY2025
Nov 10, 2025
EPS Actual
-$0.64
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$1.13
EPS Est.
-$0.25
EPS Surpr.
-352.1%
Revenue
—
Q2 FY2025
Apr 25, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.30
EPS Surpr.
+70.0%
Revenue
—
Q1 FY2025
Mar 27, 2025
EPS Actual
-$0.19
EPS Est.
-$0.19
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.56
EPS Est.
-$0.59
EPS Surpr.
+5.1%
Revenue
—
Q3 FY2024
Aug 12, 2024Miss
EPS Actual
-$0.86
EPS Est.
-$0.76
EPS Surpr.
-13.2%
Revenue
—
Q2 FY2024
May 13, 2024Miss
EPS Actual
-$0.83
EPS Est.
-$0.74
EPS Surpr.
-12.2%
Revenue
—
Q1 FY2024
Mar 25, 2024Miss
EPS Actual
-$0.74
EPS Est.
-$0.68
EPS Surpr.
-8.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2026 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q2 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q1 FY2026 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Q4 FY2025 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2025 | $-0.24 | $-0.13 | $-0.02 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2025 | Nov 10, 2025 | — | $93.80 | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -352.1% | $93.80 | — | — |
| ▲ Q2 FY2025 | Apr 25, 2025 | +70.0% | $95.20 | $93.80 | -1.47% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +0.0% | $87.85 | $88.55 | +0.80% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +5.1% | $92.05 | $93.10 | +1.14% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -13.2% | $59.15 | $60.20 | +1.78% |
| ▼ Q2 FY2024 | May 13, 2024 | -12.2% | $694.05 | $669.90 | -3.48% |
| ▼ Q1 FY2024 | Mar 25, 2024 | -8.8% | $902.30 | $943.25 | +4.54% |
Q4 FY2025—
Report Date
Nov 10, 2025
EPS Beat/Miss
—
Price Before
$93.80
Price After
—
Q3 FY2025—
Report Date
Aug 11, 2025
EPS Beat/Miss
-352.1%
Price Before
$93.80
Price After
—
Q2 FY2025-1.47%
Report Date
Apr 25, 2025
EPS Beat/Miss
+70.0%
Price Before
$95.20
Price After
$93.80
Q1 FY2025+0.80%
Report Date
Mar 27, 2025
EPS Beat/Miss
+0.0%
Price Before
$87.85
Price After
$88.55
Q4 FY2024+1.14%
Report Date
Nov 12, 2024
EPS Beat/Miss
+5.1%
Price Before
$92.05
Price After
$93.10
Q3 FY2024+1.78%
Report Date
Aug 12, 2024
EPS Beat/Miss
-13.2%
Price Before
$59.15
Price After
$60.20
Q2 FY2024-3.48%
Report Date
May 13, 2024
EPS Beat/Miss
-12.2%
Price Before
$694.05
Price After
$669.90
Q1 FY2024+4.54%
Report Date
Mar 25, 2024
EPS Beat/Miss
-8.8%
Price Before
$902.30
Price After
$943.25
Avg Beat Reaction+0.16%
Avg Miss Reaction+0.95%
Beat Rate3 / 8 quarters
Largest Move+4.54% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AVTE ends December
Aerovate Therapeutics, Inc. (AVTE) most recently reported earnings on November 10, 2025 for Q4 FY2025, posting EPS of $-0.64 (in line with the analyst consensus of —).
Each quarter, investors track AVTE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AVTE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AVTE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AVTE earnings · 4 questionsAerovate Therapeutics, Inc.'s next earnings report is expected around TBD. AVTE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AVTE historically reports after market close (AMC).
AVTE earnings datewhen is AVTE earningsAVTE next earnings datewhen does AVTE report earningsAVTE earnings calendar
▸ Source: FMP · Aerovate Therapeutics, Inc. SEC filings · US GAAP · Aerovate Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026